Observational study reveals small average weight changes post-discontinuation of semaglutide, indicating treatment variations in clinical practice.
In this large sample of patients who discontinued semaglutide or tirzepatide, reinitiation of the original medication or receipt of alternative obesity treatment was common. The average weight change 1-year post-discontinuation was relatively small; however, there was considerable individual-level variability.
No takes yet. Share an insight, caveat, or question.
Gasoyan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: